See article by Naitoh et al. [7] ( pages 51 -57) in this interventions including powerful vasodilators and issue.
inodilators that exert positive effects on hemodynamics Improving survival in congestive heart failure is currentand exercise, adversely affect survival [8] [9] [10] . At this ly based on blunting the effects of inappropriately inpoint there is therefore no universally agreed upon surrocreased adrenergic drive, as well as of increased circulating gate measure for the evaluation of new therapy in heart and tissue levels of angiotensin II and aldosterone [1-failure, but most investigators would probably agree that a 5].The sympathetic nervous system and renin-angiotensin reduction in left ventricular volume or mass, coupled with system comprise two of the three components of the a fall in plasma levels of ANP or BNP (reflecting both 'neurohumoral axis' originally proposed as links to the reduced wall stress and a de-induction of fetal gene fundamental pathophysiology of heart failure in 1984 [6] .
programs associated with maladaptive hypertrophy) are as The third component of that axis as originally postulated close to meaningful surrogates as we have. was arginine vasopressin (AVP). Research into the possible AVP is a desirable candidate for neurohumoral targeting role of AVP in heart failure has been hampered until in CHF for several reasons. Firstly, through the V1a comparatively recently by the absence of appropriate receptor it is capable of producing significant vasoconstricantagonists. Now, however, highly effective antagonists of tion, thereby increasing afterload stress on the left ventricle the V1a and V2 receptors for AVP are available, and at [11] . Secondly, again though the V1a receptor, AVP least in preliminary human studies, are safe and well directly stimulates protein synthesis within the myocyte, an tolerated. The study by Naitoh in the current issue of effect sharing similar intracellular pathways as angiotensin Cardiovascular Research [7] should stimulate considerable II [12, 13] . Under conditions of reduced AII, V1a-mediated interest in further human work with these compounds.
signaling could theoretically assume greater relative and / The decision to target a 'neurohumoral' or other subor absolute importance. Thirdly, again via the V1a restance in heart failure should be based on a sound ceptor, AVP could cause significant coronary vasoconstricpathobiological rationale, coupled with evidence that tion, leading to ischemia. Fourthly, via the V2 receptor enough of the substance in question is present to produce AVP could alter serum sodium concentration and contriban adverse effect. Then one needs to perform convincing ute to volume expansion and increased ventricular prepre-clinical studies, and initially, human studies in which load. AVP is therefore capable of contributing to increased appropriate measurements are made in small series of ventricular wall stress as well as inappropriate cellular subjects. Only then can or should larger outcomes studies hypertrophy by several direct and indirect mechanisms. be undertaken. What constitutes convincing preliminary
The pathophysiologic rationale for AVP antagonism is evidence is, however, controversial. Traditionally, improvtherefore clear. Is there enough AVP mediated signaling to ing hemodynamic measurements or showing a beneficial justify attempts to interfere with it? Most preliminary effect on exercise capacity were viewed as important.
evidence would suggest an affirmative answer. AVP levels Unfortunately, angiotensin converting enzyme inhibitors, are increased in heart failure and after myocardial infarcaldosterone antagonists, and beta adrenergic blockers have tion [14] [15] [16] [17] [18] . One study showed a correlation with outlittle or no positive short term effect on hemodynamics or comes and AVP in patients with postinfarction LV dysfuncexercise, yet produce significant benefits on major outtion [19] . Acutely, infusing AVP produces adverse hemocomes such as survival and hospitalization [1] [2] [3] [4] [5] . Other dynamic effects in chronic heart failure, while antagonizing the V1a receptor produces hemodynamic benefit [20, 21] . The latter effect has been seen in humans as well and V2 antagonism also produces acute hemodynamic unneeded diuresis, but could lead to water retention if V2 benefit in experimental and human heart failure [24] [25] [26] [27] .
stimulation occurred from increased AVP levels. Pure V1a Long term, V2 receptor antagonism produces sustained antagonism like pure V2 antagonism may, therefore, be aquaresis, without measurable hemodynamic benefit [28] , unwise in a clinical setting over the long term. Adjusting but has not been investigated with concomitant standard the mix of V1a and V2 antagonism could theoretically be therapy. These studies taken together suggest that at least tied to the projected use of a given compound, i.e. more V2 as reflected by hemodynamics and water retention, the effect for sicker volume expanded patients, more V1a for plasma AVP levels seen in heart failure or post MI produce long term effects in non-volume expanded stable populaclinically relevant effects. These studies of course do not tions. address outcomes, nor have they incorporated more
The setting chosen for investigation of these agents is sophisticated surrogate measures of the sort we now would also crucial. Recent data from an acute human study in like to see.
stable chronic heart failure with conivaptan revealed The current study of Naitoh et al. is of major importance normal AVP levels at baseline, and a predominant acute V2 because it is the first long term study of a combined V1a effect [26] . This might not be encouraging for V1a and V2 antagonist (conivaptan), utilizes a well accepted antagonism or combined antagonists in this setting long model of post infarction remodeling, incorporates at least term. As therapy for CHF improves, it is more difficult to one of the critical cotherapies required in the clinical show benefits of new treatment in well-established disease setting the study is designed to model, and includes where 'reverse remodeling' is difficult to achieve. The important structural and humoral markers. The study is most likely setting in which benefit could be demonstrated significantly positive in several respects.
might therefore be either in very sick patients where both Convipatan alone decreased RV mass, but not arterial the V1a and V2 signaling might be more important, or as pressure, ANP levels or LV mass. Conivaptan combined prophylactic therapy after myocardial infarction, with the with captopril, however, decreased arterial pressure, RV current experimental study as a guide. In the former and LV mass to a greater degree than was seen with setting, clinical endpoints are easier to determine, and in captopril, and moreover, decreased ANP levels. These the latter, using MRI determined LV mass and volume, results suggest that while combined V1a and V2 antagonalong with plasma BNP or AVP, one could design a ism alone is insufficient to blunt left ventricular remodelrelatively small trial, which, if positive using these surroing, probably because of unopposed stimulation of the gates, could justify a larger clinical study. renin-angiotensin-aldosterone axis and sympathetic nerProgressive left ventricular remodeling and congestive vous system, the combination of ACEI and AVP antagonheart failure are complex yet lethal phenomena requiring ism has greater effects than either treatment alone on both sophisticated management. In the absence of firm knowldirect (mass) and indirect (ANP) measures of cardiac edge of or the ability to manipulate intracellular and remodeling. As such, the combination certainly would hold molecular processes governing cell growth, bioenergetics promise for similar investigation in humans.
and apoptosis, our therapy must be directed at the known Of course, since conivaptan is a mixed antagonist, one and accessible modulators of these processes in the circulacan not reliably distinguish V1a from V2 effects. The tion. Great improvements have been made via interfering distinction is important, since if the effect is primarily V2 with the sympathetic nervous system and the renin-anmediated, it is not clear that the overall benefit is distinct giotensin-aldosterone system. In my opinion, there is now from what might be produced by conventional diuretics or sufficient rationale and preclinical data to proceed with nitrates. Further preclinical work with pure V1a antagonadditional therapy based on interfering with AVP. ism in the same setting, or comparisons with V2 antagonists and diuretics, would help sort out these concerns.
From a clinical standpoint, the key issues for AVP References antagonism relate to which sort of antagonist to use, and in what setting. Pure V2 antagonists might not be of much antagonists. This was seen in the current study. To prevent A selective V1a antagonist would be of potentially the greatest direct myocardial benefit and would not lead to
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